ArticleInternal medicine (Tokyo, Japan)2026
New-onset Anti-melanoma Differentiation-associated Gene 5 Antibody Positive Clinically Amyopathic Dermatomyositis Following COVID-19.
Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinically Amyopathic Dermatomyositis: Epidemiology, Clinical Presentation, Pathophysiology, Treatment, and Prognosis: A Systematic Review.Rheumatology and therapy · 2026Pooled it
- How loss-of-function mutations inJournal of translational autoimmunity · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, is a life-threatening respiratory illness that shares clinical similarities with autoimmune diseases, which some patients subsequently develop. We herein report a case of an older Japanese patient who presented with skin rash, relapsing progressive interstitial lung disease, and anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody seropositivity after COVID-19 infection. Although the patient was elderly, her symptoms improved with the administration of corticosteroids, tacrolimus, and intravenous cyclophosphamide, indicating that this combination may be a viable treatment option for anti-MDA5 antibody-positive pneumonia, which is a complication of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.